OBJECTIVES:
To estimate the cost effectiveness of dienogest versus GnRH analogue (GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slovakia for 5 years time horizon. METHODS: A cost-utility Markov model based on results of randomized controlled trial (AU19) was adapted to a Slovakian setting. The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treatment of endometriosis-associated chronic pelvic pain over a 6 month period, showed no statistically significant differences in response rates. The dienogest annual relapse rate was derived from 52-weeks extension study, while relapse rates for the GnRH-a were derived from the literature. Local cost data was based on published price lists, clinical guidelines, product labels and expert opinion. QoL related utilities were derived from individual patient SF-36 scores from AU19 dataset. Effectiveness was measured in quality-adjusted life years (QALY). Time horizon was set at five years and a payers' perspective was adopted. Discount rate was 5% per year for both costs and effects according to valid Ministry of Health (MoH) guidelines for health economic evaluation. Both one-way and probabilistic sensitivity analyses were performed. RESULTS: Dienogest showed that it was cost-effective compared to a GnRH-a, with an overall cost reduction of 426 € and a QALY gain of 0.069 per patient. Cost reduction was due to both the differences in the average drug cost during the two year period and the average laparoscopy cost. In probabilistic sensitivity analysis 92 % of simulations were below 18,000 €/QALY, which is the officially published threshold for willingness to pay in Slovakia. In 79% of cases dienogest treatment was dominant over GnRH-a. CONCLUSIONS: Dienogest is a cost-effective alternative to GnRH analogue for the treatment of endometriosis-associated chronic pelvic pain in a Slovakian setting in a five-year time horizon.
PIH31

ANTI-VIRAL TREATMENT OF CHRONIC HEPATITIS C IN A PAEDIATRIC POPULATION: A COST-EFFECTIVENESS ANALYSIS
Mernagh P 1 , Norris S 2 , Del Cuore M 3 1 Health Technology Analysts, Lilyfield, NSW, Australia, 2 Health Technology Analysts, Sydney, NSW, Australia, 3 Merck Sharp & Dohme, Sydney, NSW, Australia OBJECTIVES: The majority of individuals with chronic hepatitis C virus (HCV) are adults, and there is much experience in Australia with interferon-based treatments in adults using combination pegylated-interferon and ribavirin treatment. Pegylated-interferon alfa-2b was first approved for adult use in Australia and for reimbursement in 2003. It is currently reimbursed for initial treatment, and for a single retreatment course. Nonetheless, a limited number of children and adolescents in Australia contract the disease. Currently these individuals have no registered or reimbursed approved therapies available to them. This analysis reports a cost-effectiveness analysis of a single course of initial pegylated-interferon alfa-2b therapy in paediatrics with a bodyweight of at least 27 kg, reflecting the lowest dosage that will be supplied in Australia. METHODS: A cost-utility analysis was conducted using a lifetime Markov model. Analysis of paediatric treatment versus no treatment was undertaken to determine the impact expansion of reimbursement would have on the cost-effectiveness of the total population. Data were sourced from a study assessing sustained virological response, and the literature reporting the natural history and utility weights regarding HCV. RESULTS: Downstream cost-offsets associated with treatment reduce the total incremental cost from AU$13,208 to AU$4767. These cost-offsets arose from avoidance of downstream transitions to more severe and costly states of health. Treatment was also shown to be associated with improvements in health-related quality of life due to the downstream avoidance of more serious health states as well as the obvious improvement in viral clearance. Over the lifetime of a patient, the base case analysis estimated an improvement of approximately 2.01 QALYs, generating an incremental cost-effectiveness ratio of AU$2373 per QALY. CONCLUSIONS: Expanding reimbursement to include paediatric treatment of chronic HCV is a highly costeffective way to equitably treat chronic HCV, regardless of age. 
Individual's Health -Patient-Reported Outcomes & Preference-Based Studies
PIH32 WHAT ARE THE FACTORS INFLUENCING PARENTAL APPREHENSION ABOUT CONSENTING CHILDREN TO PARTICIPATE IN PEDIATRIC OBSERVATIONAL STUDIES? A SURVEY CONDUCTED IN FRANCE WITH IN FINE PHARMA, A PHARMACIST NETWORK
BACKGROUND:
Conducting pediatric studies is complex and the most significant barrier is infant enrollment by parental consent. This obstacle is currently found both for healthy and sick infants. The reason for the parents' refusal to consent is not obvious and may be due to multiple factors. OBJECTIVES: To identify the factors influencing parents' decisions to refuse infant participation in pediatric studies. METHODS: Observational, transversal study carried out by French pharmacists randomly selected among the 2,090 pharmacies of the In fine PHARMA ® network (representative of French pharmacies in terms of geographic location and sales). Parents presenting to participating pharmacies were eligible. Data were collected through questionnaires fulfilled by participating parents. RESULTS: Twenty-one pharmacists agreed to participate and enrolled 105 participating parents. Among them, 78 (74%) filled out a questionnaire. Participating families had an average of 2.3 children, 81% were living in an urban environment, and 51% of the infants were males. Most of the parents (97%) had never enrolled their children in a study. Main deterrents to parental consent were: they viewed pediatric studies as risky (35%), they did not want their infant to be treated as an experimental animal (20%), their infant was not ill (12%), the information provided by the physician was too confusing and/or complicated (10%). Parents may have been willing to have their child participate in a study only if the study was evaluating a new drug, their child's participation would further medical research (31%), their child suffered from a severe illness (24%), and they had great confidence in their physician (22%).
CONCLUSIONS:
The results of this survey show that the factors negatively influencing parents' decisions to consent were the perceived risk presented by the studies, the lack of interest to medical research if their child was not ill, and the lack of information about the study. 
PIH34 PATIENT REPORTED REASONS FOR MEDICATION NONADHERENCE: A SURVEY
OBJECTIVES:
Medication nonadherence among patients with chronic conditions is a significant barrier to achieving therapeutic outcomes. The objective of this study was to identify patient reported factors and reasons associated with medication nonadherence. METHODS: Online cross-sectional survey of patients taking medications for seven chronic conditions: asthma/COPD, bipolar depression, cardiovascular disease, diabetes, neuropathic pain, osteoporosis, and rheumatoid arthritis. The first 50 patients to respond to the survey for each of the seven conditions were evaluated (total nϭ350). Patients provided demographic information and answered questions about their drug therapy including knowledge and satisfaction with their medications, difficulties in taking their medications, and how often they take their medication as prescribed. Adherence was defined as patients self-reporting that they always take their medication as prescribed. Nonadherence was defined as never, sometimes or often take medications as prescribed. Multivariate logistic regression was performed to identify patient factors and reasons associated with nonadherence. RESULTS: Among the 350 patients who completed the survey, the average age was 54 years (standard deviation ϩ 11 years, range 17-85 years) with the majority being female (78%), white (87%), having a some college education or more (73%) and having health insurance (87%). Approximately 58% of patients reported medication nonadherence. No significant differences were observed between adherent and nonadherent patients with regard to age, sex, race, insurance status, condition, or number of medications taken. Reasons significantly associated with nonadherence were forgetting, don't like to take pills/give injection, cost of medication, symptoms improved so stopped taking medication, side effects too severe, and poor knowledgeable about their medications. CONCLUSIONS: Medication nonadherence is common and patient reported reasons for nonadherence include motivational factors, lack of understanding or knowledge, and treatmentrelated characteristics. Interventions that motivate, educate and individualize drug therapy according to patients' preferences and affordability may improve adherence.
PIH35 THE MEASUREMENT AND VALUATION OF HEALTH STATUS USING EQ-5D IN BRAZIL: A SYSTEMATIC REVIEW
Takemoto MLS, Fernandes RA, Cukier FN, Cruz RB, Takemoto MMS, Santos PML, Tolentino ACM, Ribeiro ACP, Fernandes RRA, Moretti AIP ANOVA -Knowledge Translation, Rio de Janeiro, Brazil OBJECTIVES: The EQ-5D has been extensively used to assess health-related quality of life (HRQoL) and utility across different health condition worldwide. The aim of this study was to systematically review studies using EQ-5D in the Brazilian population. METHODS: A structured literature search was conducted using free text words related to EQ-5D and Brazil in Pubmed and LILACS database. Original research studies that reported EQ-5D results among Brazilian patients or general population were included. RESULTS: Of 23 identified papers (Pubmedϭ11, LI-LACSϭ12, 3 duplicate citations), 4 met the selection criteria, with one study reporting evidence on validity for stroke patients (Pinto 2011), one study reporting EQ-5D responses (index, VAS and self-classification) for caregivers of stroke patients (Carod-Artal 2009) and two publications of the same SF-6D study for rheumatoid arthritis (RA) patients in which EQ-5D was used as a comparison measure (Campolina 2009 and 2010). All 3 studies reported EQ-5D index, 2 of them used the UK tariff and Carod-Artal 2009 did not inform the conversion method. Mean EQ-5D index scores were 0.65 (SD 0.3) for RA patients and 0.7 (SD 0.2) for caregivers of stroke patients. The study which applied EQ-5D to stroke patients did not report the mean scores, only correlation coefficients with stroke severity and impairment on daily living activities scales. EQ-5D showed good correlation with SF-6D in the RA study and with NIH Stroke Scale and modified Barthel Index in the stroke study. Adequate convergent validity between EQ-5D and Zarit Caregiver Burden Interview was observed among caregivers of stroke patients. CONCLUSIONS: Although the EQ-5D is the most widely used generic preference-based measure of health-related quality of life, studies reporting results for Brazilian samples are still scarce. Normative reference data for the general population are not available in the published literature which makes interpreting disease-specific scores a complex task.
PIH36 THE QUALITY OF LIFE OF PATIENTS WITH THE TOP 5 DISEASES AND THE WAY TO REFLECT THE BURDEN OF DISEASES IN THAILAND: A COUNTRY-WIDE MULTICENTER EQ-5D MEASUREMENT, 2010
Wongphan T 1 , Bundhamcharoen K 2 1 Ministry of Public Health, Muang, Nonthaburi, Thailand, 2 International Health Policy Program, Nonthaburi, Thailand OBJECTIVES: Thailand's top 5 burden of diseases in 2004 (based on the protocol of global burden of diseases (GBD) 2004) were HIV/AIDS, traffic accident, stroke, diabetes mellitus, and liver cancer, accounting for 947, 718, 652, 474, 407 Disability-Adjusted Life Years(DALYs) per 1000 population, respectively. The technique used by GBD to calculate the disability weight (DW) is based on an expert panel summary. However, this study measured DW directly from the patients and compared the results. METHODS: The cross-sectional observational multicenter hospital study was conducted in 2008-2009. The 2,695 sampling patients were selected based on epidemiologic disease data from outpatient, inpatient and primary-care unit in 5 major regional hospitals throughout Thailand. Selected patients were allocated in the quota slot and completed the EQ-5D questionnaires with their capabilities. The EQ-5D states were converted to utility weight (UW) using the Thai preference method and then changed into DW with linear regression function to then compare DALYs directly to the GBD result. RESULTS: Of 2695 patients, 56.99% are male, and the age is between 1 to 100 years old. The quality of life was calculated to DW with: DW ϭ 0.688 ϩ (-0.688 x UW). The new DW differs from GBD weight from -47.21 to 53.27 percent and these changes will affect the YLD and change the DALYs -2.83 to 4.84%. CONCLUSIONS: The new DW from the diseases and their complications differ from the GBD weight. This technique has the tendency to produce more DW that GBD's. To establish the burden of diseases, we use the quality of life to reflect the true disability. The limitation that we have to improve is the way to calculate the disability weight from EQ-5D for the best prediction.
PIH37 THE ROYAL ROAD OR THE MIDDLE WAY? PUBLIC AND PATIENT PREFERENCES FOR HEALTH OUTCOMES
Versteegh M, Brouwer W institute for Health Policy & Law, Rotterdam, The Netherlands OBJECTIVES: In economic evaluations of health care interventions, outcomes are often expressed in terms of Quality-Adjusted Life-Years (QALYs). Deriving QALY weights, operationalized as preferences for health states, requires important normative choices. One important choice is the question whose preferences we wish to capture. Currently, preferences are commonly derived from the general public, rather than from actual patients. This choice, which has large consequences on final outcomes of economic evaluations, is increasingly topic of debate. In the current study, arguments for and against public preferences are discussed and alternatives are suggested. METHODS: We highlight and critically assess the different viewpoints put forward in the health economic literature regarding the public and patient perspective. Patient preferences are considered to reflect true patient experiences, but are troublesome because preference values elicited from patients are 'unusually' high due to adaptation. Public preferences are argued to be less sensitive to adaptation, but are troublesome because they do not adequately forecast experience. RESULTS: The arguments put forward in the literature do not provide straightforward support for assessing outcomes QALY weights derived the general public. The exclusion of patient values in public decision-making is not sufficiently argued. With patient preferences life saving interventions are likely to become more cost-effective. CONCLUSIONS: Arguments for and against both positions represent different normative positions regarding the appropriate measure of outcome in health care decisions. To date, the debate seems to have focused on the question which of the two would be most appropriate. However, it seems unclear why such a dichotomy would be necessary or, in fact, useful. Both public and patient preferences appear to be important sources of information for the allocation of health care resources in society. Perhaps the question should be how to intelligently combine the two.
PIH38 SELF REPORTED HEALTH STATUS AND QUALITY OF LIFE AMONG COASTAL RURAL POPULATION IN SOUTH INDIA
Muragundi PM 1 , Udupa N 2 , Naik AN 1 , Tumkur A 1 , Shetty R 3 1 Manipal College of Pharmceutical Sciences, Manipal, India, India, 2 Manipal University, Manipal, Karnataka State, India, 3 K M C, Manipal, India, India OBJECTIVES: To assess the health status and health related quality of life among rural population residing in coastal region of South India. METHODS: Randomly selected population attending health awareness camp in rural village of South India were recruited for the study. Kannada version of EQ-5D5L questionnaire was used to assess the health related quality of life. Both descriptive and VAS scores were used for assessment. The population recruited was having the age Ͼ18 years and Ͻ75 years having the family history of either diabetes, CVD or both. RESULTS: A total of 126 patients were recruited with the meanϮSD age of 45.95Ϯ13.44. The descriptive scores ranging between minimum 1 and maximum 5 for different health related quality of life indicators were, mobility score 2.11Ϯ0.88 (meanϮSD), self-care score 1.55Ϯ0.83, activity score 2.07Ϯ0.94, pain score 2.38Ϯ0.86 and anxiety score of 1.96Ϯ1.01. Among the different health states, 11,121 health state was found as more common (mode). The VAS score found to be 67.56Ϯ14.64. CONCLUSIONS: There was considerable impact of pain and activity on the health related quality of life among rural coastal population in south India who had the family history of diabetes, CVD or both. There is a need to study the risk factors and other quality of life indicators among the rural costal population in India. OBJECTIVES: Estrogen plus progestin therapies (EPT) represent the current standard of care for postmenopausal women with a uterus for the treatment of symptoms associated with menopause. While successfully treating climacteric symptoms, the presence of progestin is necessary to prevent endometrial proliferation. Progestins contained in EPT are associated with side effects such as breast pain/ tenderness and vaginal spotting/bleeding. The objective of this study was to conduct qualitative interviews with menopausal women to better understand the patient experience of breast pain and vaginal bleeding symptoms associated with EPT, and the language patients use to describe them, to inform the development of new measurement tools for these symptoms. METHODS: Fifty-nine postmenopausal women in the USA (nϭ14), China (nϭ15), Mexico (nϭ15) and Italy (nϭ15) (aged 40-63) taking EPT and experiencing breast pain and/or vaginal bleeding/spotting (47/59 were experiencing both) participated in in-depth interviews concerning their experiences of EPT and impact on quality of life. Thematic analysis was conducted to identify concepts describing the experiences of the participants using Atlas Ti. RESULTS: In all 4 countries, breast sensations experienced while taking EPT were described as 'pain and tenderness', 'feeling swollen' and 'sensitivity' to touch or contact. Vaginal bleeding and spotting were commonly described in terms of frequency, volume, colour and consistency. Frequency of both symptoms ranged from 'daily' to 'occasionally'. Both symptoms impacted on psychological well-being, activities of daily living and sex life. Items for new measurement tools were developed using this qualitative data with clinical input from experts in menopause. CONCLUSIONS: In-depth interviews with a geographically diverse sample elicited common descriptors for the symptoms of breast pain and vaginal bleeding and allowed items to be developed that are applicable across cultures, conceptually consistent and easily translated. Accurately capturing descriptors used by patients is critical to ensure new outcome tools have content validity and cross-cultural reliability.
PIH39 HOW DO POSTMENOPAUSAL WOMEN DESCRIBE BREAST PAIN AND BREAKTHROUGH BLEEDING ASSOCIATED WITH HORMONAL TREATMENTS FOR MENOPAUSAL SYMPTOMS: QUALITATIVE INTERVIEWS WITH POSTMENOPAUSAL WOMEN IN THE UNITED STATES, CHINA, MEXICO AND ITALY
